Nathalie RIZZO

Pathophysiology and Therapeutic Targets of the Blood-Brain Barrier

Main field of research: 

Neuropharmacology / cell signaling

Keywords: 

brain interfaces, psychotropic drugs, psychiatric disorders, transporters, biomarkers

ENP label: 

2015

Research Center / Institute: 

UMR-S 1144 Therapeutic Optimisation in Neuropsychopharmacology

Research Unit Code: 

UMRS1144

Our team "Pathophysiology and therapeutic targets of the blood-brain barrier" was created in 2014 with a membership of Inserm inthe new five-year plan. It comes from the team of the former Inserm U705 (ex Director Prof. JM Scherrmann) which studied for morethan 20 years mechanisms of drug exchange in brain barriers. actually, we study the variability factors of two essential functions ofthe BBB, the maintenance of brain homeostasis towards endogenous compounds and the control of brain exposure to drugs and toxicsubstances.

Leader

Leader: 

Personal

Team members: 

Fanchon BOURASSET
Stéphanie CHASSEIGNEAUX
Salvatore CISTERNINO
Benoit HOSTEN
Aude JACOB
Marie-Claude MENET
Nathalie RIZZO
Bruno SAUBAMEA
Jean-Michel SCHERRMANN
Institutions

Principal Institution: 

Inserm

Affiliated institutions: 

Université Paris Descartes
Université Paris Diderot

Doctoral School: 

MTCI 563
Laboratory

Surname: 

Variabilité de réponses aux psychotropes
Publications

Publications: 

Jacob A, Hartz AM, Potin S, Coumoul X, Yousif S, Scherrmann JM, Bauer B, Declèves X. (2011) Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids Barriers CNS. Aug 25;8:23.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X. (2012) Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. J Pharm Sci. 101:4277-92

Yousif S, Chaves C, Potin S, Scherrmann JM, Declèves X. (2012) Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation. J Neurochem. 123:491-503

Mérian J, Boisgard R, Decleves X, Thezé B, Texier I, Tavitian B. Synthetic lipid nanoparticles targeting steroid organs. J Nucl Med. 2013 Nov;54(11):1996-2003.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X. A Physiologically Based Modeling Strategy during Preclinical CNS Drug Development. Mol Pharm. 2014 Jan 29.

Lloret-Linares C, Luo H, Rouquette A, Labat L, Poitou C, Tordjman J, Bouillot JL, Mouly S, Scherrmann JM, Bergmann JF, Declèves X. The effect of morbid obesity on morphine glucuronidation.Pharmacol Res. 2016 Sep 5. pii: S1043-6618(16)30855-6. doi: 10.1016/j.phrs.2016.08.031.